D1 versus D2 lymphadenectomy for gastric cancer

Journal of Surgical Oncology

Volumn 107, Issue 3, 2013, Pages 259-264

  Schmidt, Benjamin ^a   Yoon, Sam S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

gastric adenocarcinoma; lymphadenectomy; stage; surgery; survival

Indexed keywords

CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL (TOPIC); D1 LYMPH NODE DISSECTION; D2 LYMPH NODE DISSECTION; GASTRECTOMY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; MARUYAMA INDEX; OVERALL SURVIVAL; PRIORITY JOURNAL; RATING SCALE; REVIEW; SAFETY; STOMACH ADENOCARCINOMA; STOMACH CANCER;

ADENOCARCINOMA; HUMANS; LYMPH NODE EXCISION; STOMACH NEOPLASMS;

EID: 84873414072     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23127     Document Type: Review

References (60)

1. Bonenkamp JJ, Songun I, Hermans J, et al.: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745-748.
2. Cuschieri A, Fayers P, Fielding J, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial.The Surgical Cooperative Group. Lancet 1996; 347: 995-999.
3. Jemal A, Bray F, Center MM, et al.: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Lin Y, Ueda J, Kikuchi S, et al.: Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol 2011; 17: 4421-4428.
5. Lee J, Demissie K, Lu SE, et al.: Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 2007; 14: 78-85.
6. Siegel R, Naishadham D, Jemal A:, Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
7. Pisters PWT, Kelsen DP, Teper JE:, Cancer of the Stomach. In:, DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: Principles & practice of oncology. 9th edition ed. Philadelphia: Lippincott Williams & Wilkins; 2008. pp. 1741-1794.
8. Hamashima C, Shibuya D, Yamazaki H, et al.: The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008; 38: 259-267.
9. Lee KS, Oh DK, Han MA, et al.: Gastric cancer screening in Korea: Report on the national cancer screening program in 2008. Cancer Res Treat 2011; 43: 83-88.
10. Suzuki H, Gotoda T, Sasako M, et al.: Detection of early gastric cancer: Misunderstanding the role of mass screening. Gastric Cancer 2006; 9: 315-319.
11. Ahn HS, Lee HJ, Yoo MW, et al.: Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg 2010; 98: 255-260.
12. Ma JL, Zhang L, Brown LM, et al.: Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality. J Natl Cancer Inst 2012; 104: 488-492.
13. Asaka M, Kato M, Graham DY:, Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med 2010; 49: 633-636.
14. Kajitani T:, The general rules for the gastric cancer study in surgery. Jpn J Surg 1973; 3: 61-71.
15. Nishi M, Omori Y, Miwa K:, Japanese classification of gastric carcinoma. Tokyo: Kanehara & Co., Ltd; 1995.
16. Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101-112.
17. Sano T, Aiko T:, New Japanese classifications and treatment guidelines for gastric cancer: Revision concepts and major revised points. Gastric Cancer 2011; 14: 97-100.
18. Japanese Gastric Cancer Association, Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-123.
19. Maruyama K, Okabayashi K, Kinoshita T:, Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987; 11: 418-425.
20. Kampschoer GH, Maruyama K, van d V, et al.: Computer analysis in making preoperative decisions: A rational approach to lymph node dissection in gastric cancer patients. Br J Surg 1989; 76: 905-908.
21. Sasako M, McCulloch P, Kinoshita T, et al.: New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995; 82: 346-351.
22. Siewert JR, Kelsen D, Hoelscher AH:, Gastric cancer diagnosis and treatment-an interactive training program. Berlin: Springer Electronic Media; 2000.
23. Guadagni S, de MG, Catarci M, et al.: Evaluation of the Maruyama computer program accuracy for preoperative estimation of lymph node metastases from gastric cancer. World J Surg 2000; 24: 1550-1558.
24. Birkmeyer JD, Siewers AE, Finlayson EV, et al.: Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137.
25. Smith DL, Elting LS, Learn PA, et al.: Factors influencing the volume-outcome relationship in gastrectomies: A population-based study. Ann Surg Oncol 2007; 14: 1846-1852.
26. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
27. Park DJ, Lee HJ, Kim HH, et al.: Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005; 92: 1099-1102.
28. Sano T, Sasako M, Yamamoto S, et al.: Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 2004; 22: 2767-2773.
29. Marcus SG, Cohen D, Lin K, et al.: Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg 2003; 7: 1015-1022.
30. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 7th edition ed. New York, NY: Springer; 2010.
31. Smith DD, Schwarz RR, Schwarz RE:, Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: Data from a large US-population database. J Clin Oncol 2005; 23: 7114-7124.
32. Bouvier AM, Haas O, Piard F, et al.: How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002; 94: 2862-2866.
33. Estes NC, Macdonald JS, Touijer K, et al.: Inadequate documentation and resection for gastric cancer in the United States: A preliminary report. Am Surg 1998; 64: 680-685.
34. Reid-Lombardo KM, Gay G, Patel-Parekh L, et al.: Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base. J Gastrointest Surg 2007; 11: 410-419.
35. Mullaney PJ, Wadley MS, Hyde C, et al.: Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Union Internacional Contra la Cancrum/American Joint Committee on Cancer. Br J Surg 2002; 89: 1405-1408.
36. Wang J, Dang P, Raut CP, et al.: Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database. Ann Surg 2012; 255: 478-485.
37. Gunderson LL, Sosin H:, Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982; 8: 1-11.
38. D'Angelica M, Gonen M, Brennan MF, et al.: Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-816.
39. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
40. Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530.
41. Bonenkamp JJ, Hermans J, Sasako M, et al.: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
42. Maruyama K, Sasako M, Kinoshita T, et al.: Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995; 19: 532-536.
43. Uyama I, Ogiwara H, Takahara T, et al.: Spleen- and pancreas-preserving total gastrectomy with superextended lymphadenectomy including dissection of the para-aortic lymph nodes for gastric cancer. J Surg Oncol 1996; 63: 268-270.
44. Biffi R, Chiappa A, Luca F, et al.: Extended lymph node dissection without routine spleno-pancreatectomy for treatment of gastric cancer: Low morbidity and mortality rates in a single center series of 250 patients. J Surg Oncol 2006; 93: 394-400.
45. Yu W, Choi GS, Chung HY:, Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006; 93: 559-563.
46. Karpeh MS, Leon L, Klimstra D, et al.: Lymph node staging in gastric cancer: Is location more important than Number? An analysis of 1,038 patients. Ann Surg 2000; 232: 362-371.
47. Bunt AM, Hermans J, Smit VT, et al.: Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995; 13: 19-25.
48. Putchakayala K, Difronzo LA:, D2 lymph node dissection improves staging in patients with gastric adenocarcinoma. Am Surg 2011; 77: 1326-1329.
49. Verdecchia A, Mariotto A, Gatta G, et al.: Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003; 39: 1603-1609.
50. Strong VE, Song KY, Park CH, et al.: Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010; 251: 640-646.
51. Peeters KC, Kattan MW, Hartgrink HH, et al.: Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer 2005; 103: 702-707.
52. Kattan MW, Karpeh MS, Mazumdar M, et al.: Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003; 21: 3647-3650.
53. Lee HK, Yang HK, Kim WH, et al.: Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg 2001; 88: 1408-1412.
54. Siewert JR, Bottcher K, Stein HJ, et al.: Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461.
55. Wu CW, Hsiung CA, Lo SS, et al.: Nodal dissection for patients with gastric cancer: A randomised controlled trial. Lancet Oncol 2006; 7: 309-315.
56. Roggin KK, Posner MC:, D3 or not D3. that is not the question. Lancet Oncol 2006; 7: 279-280.
57. Songun I, Putter H, Kranenbarg EM, et al.: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.
58. Degiuli M, Sasako M, Ponti A, et al.: Morbidity and mortality after D2 gastrectomy for gastric cancer: Results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol 1998; 16: 1490-1493.
59. Degiuli M, Sasako M, Calgaro M, et al.: Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004; 30: 303-308.
60. Degiuli M, Sasako M, Ponti A:, Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 2010; 97: 643-649.